Myogenes, a leading innovator in genetic testing, has been awarded a grant from Innovate UK, the UK’s innovation agency, to further develop its revolutionary Myogenes Clozapine Test for treatment-resistant schizophrenia (TRS). This cutting-edge genetic analysis tool promises to dramatically improve patient care and generate substantial cost savings for the NHS.
Myogenes Clozapine Test promises to improve outcomes for schizophrenia patients
- Thread starter Educator
- Start date